The Man’s Guide to HPV

Source: Men's HealthBy: Melaina Juntti   What men can do about HPV Michael Douglas caught major flak for saying oral sex gave him throat cancer. But if you're laughing, it's time to grow up. Oral cancers caused by the sexually transmitted human papillomavirus (HPV) have skyrocketed 225 percent in the past 15 years, with men accounting for 75 percent of all cases. The number-one culprit: HPV passed via oral sex. It used to be that cigarettes caused most of these cancers. But since smoking rates have plummeted over the past few decades, and we're having way more oral sex today than even our fathers' generation, HPV has become the most common STD in the U.S. – inevitably leading to more oral cancer cases. It only takes one time going down on someone to contract HPV, and experts estimate that 80 percent of us will be exposed to the virus at some point in our lives. This STD sometimes causes genital warts, but according to the Centers for Disease Control and Prevention, that's not very common. In most cases, HPV has no symptoms. And since no test exists to detect HPV in guys, you won't know you have the virus until years later – if it turns into cancer. "It's very hard to determine when you acquired HPV," says Dr. William Schaffner, chairman of the Department of Preventive Medicine at Vanderbilt University. "It doesn't usually come from just one sexual episode. That said, every once in a while, cancer develops within [...]

2013-06-10T11:35:49-07:00June, 2013|OCF In The News|

HPV vaccine reduced further disease in women treated for cancer precursors

Source: www.hemonctoday.com Author: staff HPV vaccine quadrivalent (types 6, 11, 16 and 18) decreased HPV-related disease in women previously treated for cancer precursors, according to the post-hoc analysis of findings from two trials. Warner Huh, MD, associate professor in the department of obstetrics and gynecology at the University of Alabama at Birmingham, presented these findings at The Society for Gynecologic Oncologists’ 2010 Annual Meeting on Women’s Cancer in San Francisco. Although the HPV4 (Merck, Gardisil) has been shown to prevent cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts and adenocarcinoma, it is unclear if the vaccine may benefit patients who have already been exposed to the virus and had subsequent surgery. Researchers analyzed data from 17,622 women who were randomly assigned to the HPV4 or placebo. Overall, 587 women assigned to the vaccine and 763 assigned to placebo underwent cervical definitive therapy. Patients in the placebo group were at higher risk for incidence of CIN, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts and adenocarcinoma at a rate of 11.1 per 100 person-years, with an average of 1.4 years after surgery, compared with patients assigned to HPV4. Regardless of causal HPV type, patients who were vaccinated had a reduced risk for developing further disease, with a rate of 45% (95% CI, 21-62). Women treated for vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia and genital warts assigned to placebo had the highest risk for further disease, with a rate of 33.7 per 100 person-years. The risk for further [...]

Go to Top